Blog
RSS FeedPosted by Michael Wonder on 06 Dec 2024
Government of Canada signs bilateral agreement with Alberta to improve access to drugs for rare diseases
5 December 2024 - Today, the Honourable Mark Holland, Canada's Minister of Health, and the Honourable Adriana LaGrange, Alberta's Minister ...
Posted by Michael Wonder on 30 Jul 2024
HLS announces reimbursement for Vascepa under Alberta's Provincial Drug Plan
29 July 2024 - With the addition of Alberta's public plan, Vascepa will be available to more than 90% of ...
Posted by Michael Wonder on 07 Aug 2023
Alberta will cover pricey drug believed to extend and enhance lives of ALS patients
7 August 2023 - People diagnosed with ALS are usually given two to five years to live. ...
Posted by Michael Wonder on 10 Mar 2023
Alberta’s import of children’s medication to cost taxpayers $80 million
9 March 2023 - Alberta taxpayers are on the hook for $80 million, after Health Minister Jason Copping finally revealed ...
Posted by Michael Wonder on 03 Dec 2022
AbbVie announces provincial reimbursement for Rinvoq (upadacitinib) for the treatment of rheumatoid arthritis and psoriatic arthritis in Alberta, New Brunswick, Ontario, Quebec and Saskatchewan
1 December 2022 - AbbVie today announced that Rinvoq is now listed as a special authorisation medication or exception medication status ...
Posted by Michael Wonder on 12 Jul 2022
Alberta expands access to cystic fibrosis drug Trikafta for children 6 to 11
11 July 2022 - Children with cystic fibrosis can now live 'longer, healthier and fuller lives,' says advocate. ...
Posted by Michael Wonder on 03 May 2022
Boehringer Ingelheim Canada announces reimbursement for Ofev (nintedanib) in seven public drug plans for the treatment of progressive fibrosing interstitial lung diseases
3 May 2022 - Boehringer Ingelheim is pleased to announce that Ofev (nintedanib), is now available for public reimbursement in Quebec, ...
Posted by Michael Wonder on 28 Apr 2022
Baqsimi (nasal glucagon), rescue treatment for severe hypoglycaemia now covered in British Colombia, Alberta & Saskatchewan
27 April 2022 - Lilly Canada is pleased to announce that as of 5 April 2022, Baqsimi (glucagon nasal powder) ...
Posted by Michael Wonder on 02 Mar 2022
Teva Canada welcomes public drug plan reimbursement by Alberta, Saskatchewan, Québec, Veteran Affairs Canada and the non-insured health benefits program for patients prescribed Ajovy (fremanezumab) for the preventive treatment of migraine in adults
2 March 2022 - Public formulary and program coverage makes AJOVY® accessible to more migraine patients across Canada. ...
Posted by Michael Wonder on 03 Nov 2021
Valeo Pharma obtains public reimbursement for Enerzair Breezhaler and Atectura Breezhaler in Alberta
3 November 2021 - First provincial public listing secured for both asthma medications. ...
Posted by Michael Wonder on 11 May 2021
Alberta faces shortage of COVID-19 drug as global demand spikes
11 May 2021 - Provinces with highest case rates hit by shortage of medication for sickest patients. ...
Posted by Michael Wonder on 06 May 2021
Alberta, Canada, begins mandating switches from originator to biosimilar Humira
6 May 2021 - Alberta, Canada becomes the latest province to begin switching patients from originator adalimumab (Humira) to biosimilar ...
Posted by Michael Wonder on 29 Mar 2021
Alberta family waiting on approval for expensive, life-saving drug for young boy
23 March 2021 - Reign Johnston turned 2 on March 5. One of his grandpas and an uncle came to ...
Posted by Michael Wonder on 28 Jan 2021
Alberta announces funding for pricey gene therapy drug Zolgensma
Alberta Health Minister Tyler Shandro announced funding Wednesday for the gene therapy Zolgensma, which is used to treat toddlers with ...
Posted by Michael Wonder on 05 Nov 2020
Alberta, Canada sees early success from switching patients to biosimilars
5 November 2020 - Following the launch of its Biosimilars Initiative in December 2019, Alberta, Canada, has succeeded in switching 16% ...